GUBRAC Stock Overview
Operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 256.00 |
| 52 Week High | DKK 256.00 |
| 52 Week Low | DKK 256.00 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -14.09% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 63.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| GUBRAC | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.6% | -1.4% |
| 1Y | n/a | -40.5% | 6.3% |
Return vs Industry: Insufficient data to determine how GUBRAC performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how GUBRAC performed against the UK Market.
Price Volatility
| GUBRAC volatility | |
|---|---|
| GUBRAC Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GUBRAC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GUBRAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 220 | Henrik Blou | www.gubra.dk |
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging.
Gubra A/S Fundamentals Summary
| GUBRAC fundamental statistics | |
|---|---|
| Market cap | DKK 7.90b |
| Earnings (TTM) | -DKK 44.52m |
| Revenue (TTM) | DKK 205.01m |
38.5x
P/S Ratio-177.5x
P/E RatioIs GUBRAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBRAC income statement (TTM) | |
|---|---|
| Revenue | DKK 205.01m |
| Cost of Revenue | DKK 90.07m |
| Gross Profit | DKK 114.94m |
| Other Expenses | DKK 159.46m |
| Earnings | -DKK 44.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -2.73 |
| Gross Margin | 56.07% |
| Net Profit Margin | -21.72% |
| Debt/Equity Ratio | 0% |
How did GUBRAC perform over the long term?
See historical performance and comparison